Project Grant HT94252510690
Award Date
7/15/25
Completion Date
7/14/29
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
This Project Grant award for $798,673.00, awarded on July 15, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to characterize the role of aberrant FGD1 splicing in brain and bone metastasis in clear cell renal cell carcinoma. The research will be conducted over a period of nearly 4 years, with a final completion date of June 14, 2029. As a...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $328,574.00 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to conduct research on "Quantifying Spatial Properties of Immunosuppressive Macrophages in Papillary Renal Cell Carcinoma". The award period runs from July 1, 2025 to June 30, 2028. This grant supports advanced biomedical research...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,339,689 to The Feinstein Institutes For Medical Research to conduct research on identifying and characterizing tumor cell subpopulations that drive metastasis in localized stage III clear cell renal cell carcinoma. The research aims to advance understanding of this aggressive form of kidney cancer and develop innovative therapeutic approaches....
This federal Project Grant award, valued at $168,500.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida, to cotarget Type 1 PRMTS and YAP1 in order to combat EGFR-mutant lung adenocarcinoma. The grant period runs from September 1, 2024 to August 31, 2025. The Moffitt Cancer Center is a nonprofit,...
The U.S. Department of Defense's Defense Health Agency has awarded a $762,168 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. under the Military Medical Research and Development (CFDA 12.420) program. The grant, with a project period from September 30, 2023 to September 29, 2026, is intended to "DECONVOLUTE KEY BIOLOGICAL DRIVERS THAT DEFINE SUBSETS OF LETHAL PROSTATE CANCER IN AFRICAN AMERICAN MEN." As a leading National Cancer...
The U.S. Department of Defense's Defense Health Agency awarded a $481,749 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective September 30, 2023 through September 29, 2026, will support research to dissect the spatial molecular architecture of the transformed cutaneous T cell lymphoma tumor microenvironment, with the goal of identifying novel...
This federal Project Grant award of $1,619,065.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the "DYNAMIC: DEVELOPMENT OF A BEHAVIORAL INTERVENTION FOR YOUNG ADULTS WITH ADVANCED CANCER" project at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project aims to develop and evaluate a behavioral intervention for young adult cancer patients, with a...
This federal Project Grant award of $968,875.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The grant will fund a 3-year project focused on the identification and assessment of targets for immunotherapy in NF2-associated schwannomatosis, a rare genetic disorder. The research aims to advance the understanding and treatment of...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $2,837,644 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding will support "Translational Studies for Targeted Alpha-Particle Therapy for Rare Melanomas" over a 4-year period from September 1, 2023 to August 31, 2027. This project grant aims to advance research into innovative cancer therapies, specifically exploring...
This Project Grant award of $1,221,625.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop novel genetic mouse models for studying the progression and metastasis of uveal melanoma. The award period runs from June 1, 2024 to May 31, 2027. Moffitt Cancer Center is a prominent National Cancer Institute-designated comprehensive cancer center...